The researchers used administrative medical claims data from the Thomson Reuters Market Scan databases, selected the healthcare experience of 17 million enrollees from over 100 large U.S. Employers, patient samples for the study. Patients who had at least one inpatient or outpatient lupus two claims were matched with no no evidence of disease, but were similar in other respects .
Using similar methods, the authors found that patients with asthma annual costs of $ 8,907 had diabetic patients. Had an annual cost of $ 14,709 and heart disease patients had annual costs of 17 The authors also examined the cost burden per employee, more than 50,000 people cost per patient with the condition and the prevalence of it condition. Since lupus is relatively rare, the average cost of lupus per employee 312th 22 The average cost per employee for asthma was $ 191 for heart disease, this was $ 312th.
The Healthcare business of Thomson Reuters (conducted the study in collaboration with researchers from the University of California at San Francisco, Emory University and Bristol-Myers Squibb, which funded the research..Poster Session 1, Tuesday, October 2013: Defibrotide downregulates heparanase expression into tumor cells . Echart co. Gentium SpA, Italy. – Defibrotide protecting endothelial cells from complications stem cell transplantation . Echart et al. Gentium SpA, Italy. – Oral Presentation Hall A, Wednesday, October 2013:.
With the Securities and Exchange Commission under the heading Risk Factors . Source: Gentium S.. Forward-looking statements from preclinical and clinical data on Defibrotide Am the thirty third World Congress International Society of Hematology Gentium SpA announced that it two posters and an oral presentation to of Defibrotide imagined World Congress on World Congress of the International Society of Haematology at the ICC Jerusalem International Convention Center at Jerusalem, October 10-13, 2013.
Notice regarding Forward Looking StatementsThis press release includes forward-looking statements .